{
    "concepts": [],
    "broad_search": {
        "queries": [
            {
                "query_id": "q1",
                "search_terms": [
                    "asbestos",
                    "talc",
                    "mesothelioma",
                    "cancer",
                    "genomic",
                    "genetic"
                ],
                "query_expression": "(cancer causation AND (genetic predisposition OR genetic susceptibility OR BAP1 OR NF2 OR CDKN2A OR TP53 OR BRCA1 OR BRCA2)) OR ((lung cancer OR ovarian cancer) AND (genetic predisposition OR genetic susceptibility OR BAP1 OR NF2 OR CDKN2A OR TP53 OR BRCA1 OR BRCA2)) OR (mesothelioma OR asbestosis OR \"pleural plaque\" OR \"pleural plaques\" OR \"pleural disease\" OR \"pleural thickening\") OR (asbestos OR talc)",
                "rationale": "This query combines the core exposure agents (asbestos, talc, mesothelioma) with the broadest terms for the scientific focus (cancer, genomic, genetic). It captures all literature related to asbestos/talc exposures and mesothelioma in the context of cancer and genomics/genetics, ensuring coverage of all specified topics including susceptibility, mutations, biomarkers, and regulatory science.",
                "covered_topics": [
                    "t001",
                    "t002",
                    "t003",
                    "t004",
                    "t005",
                    "t006",
                    "t007",
                    "t008",
                    "t009",
                    "t010",
                    "t011",
                    "t012"
                ],
                "estimated_weekly_volume": 100,
                "semantic_filter": {
                    "enabled": true,
                    "criteria": "# **Knowledge Horizon Semantic Filter - Comprehensive Prompting Language**\n\n## **MISSION STATEMENT**\n\nYou are evaluating scientific articles for Knowledge Horizon, a literature monitoring service for legal teams defending asbestos and talc litigation. Your role is to identify articles providing information **directly usable by defense counsel** in toxic tort cases.\n\n**Key Principles:**\n- Include articles supporting **both defense and plaintiff positions** (comprehensive awareness, not selective reporting)\n- Quality is NOT a filter criterion (defendants need awareness of low-quality studies that could be used against them)\n- Default to **inclusion when uncertain** if a reasonable litigator could find it useful\n- Score articles based on **litigation utility**, not scientific merit\n\n---\n\n## **MANDATORY INCLUSION CRITERIA**\n\n### **ALWAYS INCLUDE - Score 0.8-1.0**\n\n**1. Exposure, Migration & Fiber Behavior**\n- ANY article dealing with exposure to, migration of, or behavior of elongated mineral particles (asbestos, talc, or related minerals)\n- Fiber transport, deposition, clearance, biopersistence\n- Occupational, consumer product, environmental, or bystander exposure\n- Exposure reconstruction, measurement, or assessment methodologies\n- Background/ambient exposure levels\n- Historical exposure documentation\n\n**2. Risk & Causation**\n- Risk quantification or dose-response relationships\n- Causation frameworks (Bradford Hill criteria, attribution methodology)\n- Alternative causation evidence (especially genetic predisposition)\n- Disease mechanisms linking exposure to disease\n- Fiber potency comparisons (chrysotile vs. amphibole)\n\n**3. Regulatory & Standards**\n- OSHA, EPA, FDA, IARC regulatory actions or guidance\n- Permissible exposure limits\n- Testing standards and protocols\n- Asbestos detection methods in talc products\n\n---\n\n## **DISEASE-SPECIFIC INCLUSION RULES**\n\n### **Core Diseases of Interest**\n- Mesothelioma (all types: pleural, peritoneal)\n- Asbestosis\n- Lung cancer (in context of asbestos/talc exposure)\n- Ovarian cancer (in context of talc exposure)\n- Pleural diseases related to asbestos/talc\n\n**Other cancers:** Include ONLY if they involve genetic predisposition or susceptibility arguments generalizable to mesothelioma, ovarian cancer, or lung cancer.\n\n---\n\n## **REFINED CRITERIA FOR PROBLEMATIC CATEGORIES**\n\n### **1. PROGNOSIS & DIAGNOSIS ARTICLES**\n\n**INCLUDE - Score 0.6-0.8 IF:**\n\n\u2705 **Differential diagnosis** - Distinguishing asbestos/talc-related disease from other causes\n- Diagnostic criteria affecting causation assessment\n- Helps establish/challenge causation in individual cases\n- Could affect case selection or expert testimony\n\n\u2705 **Prognosis relevant to damages** - Survival rates, disease progression, quality of life\n- Could affect damages calculations or settlement valuations\n- Disease-specific survival by stage/histology\n- Information defendants need to evaluate case value\n\n\u2705 **Diagnostic biomarkers** - Tests establishing/challenging exposure or disease\n- Fiber burden analysis\n- Pleural plaque identification\n- Exposure biomarkers\n\n**EXCLUDE - Score 0.3 or FAIL IF:**\n\u274c Pure treatment efficacy without damages/prognosis implications\n\u274c Clinical management decisions with no litigation relevance\n\u274c Diagnostic techniques that don't affect causation assessment\n\u274c Therapeutic target identification without causation implications\n\n**DECISION TEST:** *\"Would this information be useful in evaluating a defendant's potential damages exposure or in challenging/supporting causation claims?\"*\n\n**SCORING EXAMPLES:**\n- Survival analysis by histology \u2192 0.7 (damages assessment)\n- Differential diagnosis mesothelioma vs. adenocarcinoma \u2192 0.8 (causation)\n- New chemotherapy regimen efficacy \u2192 FAIL (treatment only)\n- Prognostic biomarker (no causation link) \u2192 0.4-0.5 (edge case)\n\n---\n\n### **2. CASE REPORTS**\n\n**DEFAULT: INCLUDE virtually ALL case reports of diseases of interest**\n\n**Score 0.7-0.8 IF:**\n\u2705 **Substantial exposure documentation**\n- Detailed occupational history\n- Product use documentation\n- Fiber burden analysis or tissue samples\n- Environmental exposure assessment\n\n**Score 0.5-0.6 (EDGE) IF:**\n\u2705 **Minimal exposure mention**\n- Brief occupational history\n- Self-reported exposure without validation\n- Disease presentation without detailed exposure data\n\n**Score 0.7-0.8 IF (regardless of exposure):**\n\u2705 **Genetic information present**\n- Germline mutations (BAP1, CDKN2A, NF2, TP53)\n- Family history of mesothelioma/cancer\n- Genetic testing results\n\n\u2705 **Unusual presentation suggesting alternative causation**\n- Young age at diagnosis\n- Minimal documented exposure (challenges dose-response)\n- Atypical disease features\n\n**RARE EXCLUSIONS - Score 0.3 or FAIL:**\n\u274c Pure treatment case reports with NO exposure, diagnostic, or genetic information\n\u274c Case reports of completely unrelated diseases where asbestos mention is purely incidental\n\n**DEFAULT RULE:** When in doubt about a case report, **INCLUDE IT** and score 0.5-0.6.\n\n**SCORING EXAMPLES:**\n- Mesothelioma case with detailed brake mechanic history \u2192 0.8\n- Mesothelioma case with BAP1 mutation, minimal exposure \u2192 0.8\n- Mesothelioma case with \"worked in construction\" only \u2192 0.5-0.6\n- Mesothelioma case, no exposure/genetic info \u2192 0.4 (edge, likely include)\n- Lung cancer case, incidental mention of past asbestos \u2192 FAIL\n\n---\n\n### **3. HISTORY-TAKING FORMS & QUESTIONNAIRES**\n\n**INCLUDE - Score 0.6-0.8 IF:**\n\n\u2705 **Exposure assessment methodology**\n- Industrial hygiene questionnaires\n- Occupational history protocols  \n- Exposure reconstruction techniques\n- Validation of self-reported exposure data\n- Standardized methods for documenting exposure\n\n\u2705 **Defense-relevant information**\n- Shows what exposure questions are scientifically valid\n- Reveals what exposure assessment methods are being used\n- Provides framework for evaluating claimed exposures\n\n**EXCLUDE - Score 0.4 or FAIL IF:**\n\u274c Primarily designed for plaintiff case selection/screening\n\u274c Focuses on identifying \"good cases\" for litigation\n\u274c No methodological content for exposure reconstruction\n\u274c Purely administrative or intake forms without scientific content\n\n**DECISION TEST:** *\"Would a defense industrial hygienist or exposure reconstruction expert find this useful for understanding how exposure is being scientifically assessed?\"*\n\n**SCORING EXAMPLES:**\n- \"Validation of asbestos exposure questionnaire for case-control studies\" \u2192 0.7 (methodology)\n- \"Standardized occupational history protocol for chrysotile exposure\" \u2192 0.8 (exposure assessment)\n- \"Development of history-taking form for mesothelioma patients at risk\" \u2192 0.4-0.5 (edge, likely plaintiff-focused)\n- \"Law firm mesothelioma case intake protocols\" \u2192 FAIL (pure case selection)\n\n---\n\n### **4. CELLULAR & MOLECULAR MECHANISMS**\n\n**CRITICAL DISTINCTION:** Mechanisms relevant to **causation arguments** vs. purely **descriptive disease biology**\n\n**INCLUDE - Score 0.7-0.9 IF:**\n\n\u2705 **Genetic determinants of disease risk**\n- Germline mutations causing disease **independent of exposure** (BAP1, CDKN2A, NF2, TP53)\n  - **These support alternative causation (pro-defense)**\n- Genetic polymorphisms **modifying exposure-related risk** (DNA repair genes, inflammatory genes)\n  - **These support susceptibility arguments (pro-plaintiff)**\n- Hereditary cancer syndromes involving mesothelioma/ovarian cancer\n- Gene-environment interactions\n\n\u2705 **Mechanisms distinguishing fiber types**\n- Why certain fibers are more pathogenic (chrysotile vs. amphibole)\n- Biopersistence differences between fiber types\n- Cellular uptake and clearance mechanisms **by fiber type**\n- Mechanistic basis for potency differences\n\n\u2705 **Mechanisms informing exposure-response**\n- How low-level exposure causes disease (or doesn't)\n- Threshold effects vs. linear no-threshold models\n- Time-to-disease mechanisms (latency periods)\n- Dose-response mechanistic pathways\n\n\u2705 **Elongated mineral particle (EMP) behavior**\n- Translocation/migration of mineral particles (including non-asbestos)\n- Fiber deposition, clearance, biopersistence\n- Mechanistic evidence plaintiffs could cite for biological plausibility\n\n**EXCLUDE - Score 0.3 or FAIL IF:**\n\n\u274c **Purely descriptive without litigation relevance**\n- General cancer biology applicable to all cancers (not asbestos/talc-specific)\n- Tumor signaling pathways without causation implications\n- Molecular pathways that don't distinguish exposed vs. unexposed populations\n- Cellular mechanisms with no implications for:\n  - Causation assessment\n  - Exposure-response relationships\n  - Genetic predisposition/susceptibility\n  - Fiber-type distinctions\n\n\u274c **Prognostic/therapeutic focus only**\n- Biomarkers for treatment response (unless also relevant to diagnosis/causation)\n- Therapeutic target identification (unless mechanistic causation link)\n- Molecular subtypes without causation framework\n- Drug development without mechanistic insights\n\n**DECISION TEST:** *\"Could this mechanistic information be used to argue FOR or AGAINST causation in a specific case, to distinguish fiber types, to support genetic alternative causation, or to inform dose-response relationships? Or does it just describe disease biology after disease has developed?\"*\n\n**SCORING EXAMPLES:**\n- \"BAP1 loss disrupts DNA damage response leading to mesothelioma independent of asbestos\" \u2192 0.9 (genetic predisposition)\n- \"DNA repair polymorphisms modify asbestos-related mesothelioma risk\" \u2192 0.8 (genetic susceptibility)\n- \"Differential inflammatory responses to chrysotile vs. amphibole fibers\" \u2192 0.8 (fiber-type distinction)\n- \"Nose-to-brain translocation of ultrafine elongated particles\" \u2192 0.7-0.8 (EMP migration)\n- \"PI3K/AKT pathway activation in mesothelioma tumor growth\" \u2192 FAIL (purely descriptive)\n- \"Autophagy regulation in cancer cell survival\" \u2192 FAIL (too general)\n- \"L1CAM expression as prognostic marker in mesothelioma\" \u2192 FAIL or 0.4 (descriptive only)\n- \"LOXL3 high expression associated with poor prognosis\" \u2192 FAIL or 0.4 (prognostic, no causation)\n\n---\n\n### **5. BAP1 TUMOR PREDISPOSITION SYNDROME (BAP1-TPDS)**\n\n**SPECIAL RULE: ALWAYS INCLUDE any BAP1-TPDS article - Score 0.7-0.9**\n\n**This includes articles about:**\n- BAP1-TPDS and meningioma\n- BAP1-TPDS and uveal melanoma\n- BAP1-TPDS and renal cell carcinoma\n- BAP1-TPDS and any other cancer\n\n**RATIONALE:** \nBAP1-TPDS establishes the genetic predisposition syndrome framework that can be used in mesothelioma defense cases to argue **alternative causation independent of asbestos exposure**, even when the specific article focuses on a different cancer type.\n\n**SCORING:**\n- BAP1-TPDS in mesothelioma context \u2192 0.9\n- BAP1-TPDS in other cancers (meningioma, melanoma, RCC) \u2192 0.7-0.8\n- BAP1 somatic mutations (not germline) \u2192 score based on causation relevance\n\n**EXAMPLES:**\n- \"High Frequency of Meningioma in BAP1-TPDS Patients\" \u2192 0.7-0.8 (establishes syndrome)\n- \"BAP1 germline mutations and mesothelioma penetrance\" \u2192 0.9 (direct relevance)\n- \"Restoration of BAP1 activity in kidney cancer\" \u2192 0.3-0.4 (somatic, treatment-focused)\n\n---\n\n### **6. EPIDEMIOLOGY & INCIDENCE STUDIES**\n\n**INCLUDE - Score 0.7-0.8 IF:**\n\n\u2705 Mesothelioma, asbestosis, or ovarian cancer incidence trends\n\u2705 Risk quantification in exposed populations\n\u2705 Geographic or temporal patterns in disease incidence\n\u2705 Cohort or case-control studies (any exposure level)\n\u2705 Meta-analyses of risk\n\n**Why relevant:** \n- Shows disease trends over time (can support declining exposure arguments)\n- Provides population-level risk data for causation arguments\n- Documents background disease rates\n\n**SCORING EXAMPLES:**\n- \"Trends in Pleural Mesothelioma Incidence in US Metropolitan Areas\" \u2192 0.8\n- \"Global patterns and trends in mesothelioma incidence\" \u2192 0.7\n- \"Retrospective epidemiological study of mesothelioma 1999-2020\" \u2192 0.7\n\n---\n\n### **7. FIBER IDENTIFICATION & ANALYTICAL METHODS**\n\n**INCLUDE - Score 0.8-1.0 IF:**\n\n\u2705 TEM, SEM, PLM, XRD methodologies for fiber identification\n\u2705 Distinguishing asbestos from non-asbestos elongate mineral particles\n\u2705 Asbestos detection in talc products\n\u2705 Classification of asbestiform vs. non-asbestiform particles\n\u2705 Laboratory quality control and proficiency testing\n\n**RATIONALE:** Critical for product contamination claims and exposure assessment\n\n**SCORING EXAMPLES:**\n- \"Dimensional differences between asbestos and cleavage fragments of amphiboles\" \u2192 1.0\n- \"Testing methods for detecting asbestos in talc-containing cosmetics\" \u2192 0.9\n\n---\n\n### **8. ANIMAL STUDIES & EXPERIMENTAL MODELS**\n\n**INCLUDE - Score 0.7-0.9 IF:**\n\n\u2705 Animal models of asbestos/talc-induced disease\n\u2705 Fiber carcinogenicity studies (including non-asbestos fibers like carbon nanotubes)\n\u2705 Comparative fiber potency studies\n\u2705 Mechanistic studies linking exposure to disease\n\n**Why include non-asbestos fiber studies:**\nPlaintiffs may draw analogies between asbestos and other fiber-induced cancers. Defense needs awareness of comparative fiber carcinogenesis.\n\n**SCORING EXAMPLES:**\n- \"Pheochromocytoma in rats: weak link in talc carcinogenicity assessment?\" \u2192 1.0 (challenges talc classification)\n- \"Gene expression in mesothelioma induced by multi-walled carbon nanotubes vs. asbestos\" \u2192 0.7 (comparative fiber biology)\n\n---\n\n## **OVERALL EXCLUSION CRITERIA**\n\n**FAIL (Score 0.0-0.3) IF:**\n\n\u274c Only mentions asbestos/talc/mesothelioma tangentially without substantive analysis\n\u274c Focus on unrelated occupational exposures or diseases\n\u274c Purely financial/investment/legal case decisions (not scientific content)\n\u274c Exact duplicate publications\n\u274c Purely advocacy without scientific data\n\u274c Treatment efficacy only (no prognosis, diagnosis, or causation implications)\n\u274c Descriptive molecular biology without causation relevance\n\n---\n\n## **SCORING CALIBRATION GUIDE**\n\n### **Score 0.9-1.0: MUST INCLUDE - Maximal Litigation Utility**\n- Direct exposure assessment or quantification\n- Fiber identification/characterization methods\n- Risk quantification with dose-response\n- Regulatory standards or guidance\n- Alternative causation evidence (genetic predisposition)\n- Asbestos contamination in talc products\n\n### **Score 0.7-0.8: STRONG INCLUDE - High Litigation Utility**\n- Epidemiological incidence/trend data\n- Diagnostic criteria for differential diagnosis\n- Prognosis relevant to damages assessment\n- Gene-environment interactions (susceptibility)\n- Case reports with substantial exposure documentation\n- BAP1-TPDS (any cancer)\n- Fiber potency comparisons\n- EMP translocation/migration studies\n\n### **Score 0.5-0.6: EDGE CASES - Moderate Utility**\n- Case reports with minimal exposure documentation\n- Survival/prognosis data with limited damages relevance\n- Biomarkers with some diagnostic utility\n- History-taking forms (if exposure methodology content)\n- General cancer genomics with weak asbestos/talc link\n\n### **Score 0.3-0.4: LIKELY FAIL - Low Utility**\n- Purely descriptive molecular biology\n- Treatment-focused without prognosis data\n- Tangential mention of asbestos/talc\n- Prognostic markers without causation link\n\n### **Score 0.0-0.2: DEFINITE FAIL - No Litigation Utility**\n- No connection to asbestos/talc/target diseases\n- Pure treatment efficacy\n- Financial/legal case decisions\n- Duplicate content\n\n---\n\n## **SPECIAL CLASSIFICATION RULES**\n\n### **Genetics Articles - TWO-STEP CLASSIFICATION**\n\n**STEP 1: Is this article relevant to asbestos/talc litigation?**\n- Does it address mesothelioma, ovarian cancer, or lung cancer genetics?\n- Does it address genetic predisposition or susceptibility?\n\n**STEP 2: Strategic Classification**\n\n**[PRO-DEFENSE: PREDISPOSITION] - Score 0.8-0.9**\n- Germline mutations causing disease **without exposure requirement**\n- BAP1, CDKN2A, NF2, TP53 hereditary syndromes\n- Familial mesothelioma clusters with minimal exposure\n- Penetrance data showing genetic causation\n- Young patients with genetic mutations, minimal exposure\n\n**Test:** *\"Does this show genetics can cause disease WITHOUT exposure?\"*\n\n**[PRO-PLAINTIFF: SUSCEPTIBILITY] - Score 0.7-0.8**\n- Genetic variants **enhancing risk FROM exposure**\n- Gene-environment interactions requiring BOTH genetics AND exposure\n- DNA repair polymorphisms modifying asbestos risk\n- Inflammatory/immune response variants affecting exposure response\n- Population susceptibility differences\n\n**Test:** *\"Does this show genetics increases risk ONLY WHEN exposed?\"*\n\n**[NEUTRAL: GENOMIC CHARACTERIZATION] - Score 0.5-0.7**\n- Tumor molecular profiling without causation framework\n- Somatic mutation patterns\n- Prognostic molecular markers\n- Therapeutic genomics\n\n**Test:** *\"Does this describe disease biology without addressing causation?\"*\n\n---\n\n## **DECISION FRAMEWORK - WHEN IN DOUBT**\n\n### **DEFAULT TO INCLUSION IF:**\n\n1. A defense attorney, expert witness, or industrial hygienist could **plausibly use it**\n2. It provides context for understanding **exposure, causation, or damages** issues\n3. It has potential **impeachment value** (showing flaws in plaintiff-cited studies)\n4. It's a **case report** with any exposure or genetic documentation\n5. It involves **genetic information** relevant to mesothelioma/ovarian cancer/lung cancer\n6. It addresses **fiber behavior, migration, or characterization** (even non-asbestos fibers)\n7. It provides **epidemiological context** (incidence, trends, risk estimates)\n\n### **DEFAULT TO EXCLUSION IF:**\n\n1. Asbestos/talc connection is **purely coincidental or tangential**\n2. It's a **duplicate** of information already captured\n3. It's **pure treatment efficacy** without prognosis/diagnosis/causation content\n4. It's **descriptive molecular biology** without causation relevance\n5. Primary topic is **completely outside litigation scope**\n\n---\n\n## **CRITICAL REMINDERS**\n\n\u2705 **Include BOTH favorable and unfavorable articles** - defense needs comprehensive awareness\n\n\u2705 **Quality is NOT a filter** - include low-quality studies plaintiffs might cite\n\n\u2705 **Case reports default to inclusion** - score 0.5-0.6 minimum if disease-relevant\n\n\u2705 **BAP1-TPDS always relevant** - even for non-mesothelioma cancers\n\n\u2705 **Prognosis = damages relevance** - score 0.6-0.7 for survival data\n\n\u2705 **Mechanistic \u2260 automatically relevant** - must relate to causation, not just describe disease\n\n\u2705 **EMP translocation matters** - even for non-asbestos particles (biological plausibility arguments)\n\n\u2705 **Exposure methodology > case selection** - include history-taking if scientific content\n\n---\n\n## **EXAMPLE SCORING DECISIONS**\n\n| Article Title | Initial Instinct | Correct Score | Rationale |\n|---------------|------------------|---------------|-----------|\n| \"Malignant mesothelioma in rare sites: case reports\" | 0.7 | **0.5-0.6** | Case report with minimal exposure - edge case |\n| \"Development of history-taking form for mesothelioma patients\" | 0.9 | **0.4-0.5 or FAIL** | Plaintiff case selection, not defense methodology |\n| \"Fibroblast-like cells in mesothelioma can derive from tumor cells\" | 0.8 | **FAIL (0.3)** | Descriptive biology, no causation relevance |\n| \"Circulating biomarkers and targeted therapy in pleural mesothelioma\" | 0.8 | **FAIL (0.3)** | Treatment focus, no causation/diagnosis relevance |\n| \"Retrospective cohort study of survival length in malignant pleural effusion\" | 0.2 | **0.6-0.7** | Survival data relevant to damages assessment |\n| \"High frequency of meningioma in BAP1-TPDS patients\" | 0.4 | **0.7-0.8** | BAP1-TPDS establishes predisposition syndrome |\n| \"Nose-to-brain translocation of ultrafine elongated particles\" | 0.5 | **0.7-0.8** | EMP migration mechanistically relevant |\n| \"Multi-omics profiling reveals molecular phenotype in pleural mesothelioma\" | 0.9 | **FAIL (0.3)** | Descriptive molecular biology, no causation link |\n| \"L1CAM expression in human tumors and prognosis\" | 0.7 | **FAIL (0.3)** | Prognostic marker only, no causation relevance |\n| \"LOXL3 high expression as biomarker in pleural mesothelioma\" | 0.8 | **FAIL (0.3)** | Prognostic marker only, no causation relevance |\n\n---\n",
                    "threshold": 0.8
                },
                "source_id": 1
            }
        ],
        "strategy_rationale": "",
        "coverage_analysis": {}
    },
    "article_limit_per_week": null
}